U.S. FDA approves Cepheid’s COVID-19 test to expand frontline testing
Category: #health  By Saipriya Iyer  Date: 2020-03-23
  • sharesocial_share_icon
  • Twitter
  • Facebook
  • LinkedIn

U.S. FDA approves Cepheid’s COVID-19 test to expand frontline testing

The U.S. FDA (Food and Drug Administration) has recently approved Cepheid’s COVID-19 test in response to the public health emergency caused by the coronavirus. The new test can help expand the availability of frontline testing in clinics and hospitals, without the need for round-tripping to a diagnostic lab. The federal agency has been rapidly focusing on granting emergency use authorization to tests and equipment to address the accelerating spread of the virus in the United States.

COVID-19 test of Cepheid has a distinct advantage over other tests, as it functions with or without the use of nasal swabs. This is considered advantageous because the nasal swabs supplies have been taxed globally. The new tests will be shipped out by the company from next week. The test, which is molecular and PCR-based, also has high level of accuracy as that of the lab-based testing in various U.S. facilities. However, it adopts Cepheid’s GeneXpert machine, which is a diagnostic kit, to ensure on-site delivery of results.

Nearly 23,000 GeneXpert micro-labs of the American molecular diagnostic company have reportedly been adopted across the world, with over 5,000 that are based in the U.S. Cepheid’s hardware has been running flu-related tests since many years and has high reliability rates.

The testing capacity in the U.S. has been increased in the past few weeks owing to widespread efforts to enhance its availability and cater to the hard-hit regions such as NYC by coronavirus pandemic. However, the demand for tests is rising continuously and this limited availability has resulted in only severe cases, with proof of elevated risk or confirmed contract tracing, being tested.

In order to effectively inform any coronavirus mitigation strategies, various testing solutions similar to that of Cepheid and other potential and accurate testing alternatives that can be carried out at home, such as the forthcoming antibodies test introduced by Scanwell, etc. are needed to expand the testing capabilities to the highest degree.

Source credit:

https://finance.yahoo.com/news/type-covid-19-test-now-134500434.html



About Author

Saipriya Iyer

Email: [email protected]   linkdin twitter

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

More News By Saipriya Iyer

 Tabletop Tape Dispensers  market valuation to surge at healthy CAGR through 2026

Tabletop Tape Dispensers market valuation to surge at healthy CAGR through 2026

By Saipriya Iyer

A comprehensive research study on Tabletop Tape Dispensers market added by Market Study Report provides insights into the market size and growth trends of this industry over the forecast timeline. The study evaluates key aspects of Tabletop Tape D...

APAC, Europe, America region to generate massive revenues for General Well-Being Dietary Supplements market by 2026

APAC, Europe, America region to generate massive revenues for General Well-Being Dietary Supplements market by 2026

By Saipriya Iyer

MarketStudyReport.com presents latest report on global General Well-Being Dietary Supplements Market, which evaluates the growth trends of the industry through historical study and estimates future prospects based on comprehensive research. The re...

Eugenia Jambolana Extract Market to Increase Exponentially During 2027

Eugenia Jambolana Extract Market to Increase Exponentially During 2027

By Saipriya Iyer

The report Eugenia Jambolana Extract market provides high-quality information regarding the major market trends, product types and their application scope, competitive landscape, and impact of COVID-19 outbreak.

.

Request a...